Company Filing History:
2 out of 832,891 Years Active: 2002-2004
Title: Innovations of Nigel Alan John McMillan in Papillomavirus Research
Introduction
Nigel Alan John McMillan, an accomplished inventor based in Woolloongabba, Australia, has made significant contributions in the field of virology with a focus on papillomavirus. With two patented innovations to his name, McMillan’s research has the potential to impact treatment and prevention strategies against HPV infections.
Latest Patents
McMillan’s latest patents revolve around the development of papillomavirus polyprotein constructs. The first patent details a papillomavirus polyprotein construct that includes at least two amino acid sequences. These sequences are either from an early ORF protein of papillomavirus or immunogenic variants or fragments thereof. Importantly, at least one of the sequences is not derived from the E6 or E7 protein sequence, emphasizing the potential for new therapeutic options. The patent also discusses nucleic acid molecules encoding these constructs, along with methods for eliciting immune responses against papillomavirus in host animals.
The second patent further develops on this theme by focusing on peptides, antibodies, and recombinant expression systems that express a DNA insert of HPV. This innovation aims to produce immunogenic compositions to inhibit and treat HPV infections as well as to address tumor initiation and progression. The patent particularly highlights the use of specific peptides and recombinant cells expressing regions of the HPV16 E6 or E7 nucleoprotein, paving the way for novel therapeutic approaches.
Career Highlights
McMillan has demonstrated a dedicated career marked by his innovative research in HPV. His work not only contributes to the academic community but also holds promise for practical applications in medicine, particularly in combatting HPV-related diseases.
Collaborations
Throughout his career, McMillan has collaborated with esteemed colleagues including Elizabeth Ann Webb and Mary Brigid Margetts. These partnerships reflect a commitment to advancing the field through shared expertise and collective research endeavors aimed at enhancing therapeutic strategies for HPV.
Conclusion
Nigel Alan John McMillan stands out as an inventive force in the area of papillomavirus research. His patents highlight his dedication to developing new treatments that could significantly impact public health. As the fight against HPV-related diseases continues, McMillan's work represents an important step forward in the ongoing battle against viral infections.